logo-loader

Propanc welcomes founding member back to scientific advisory board

Last updated: 23:49 06 May 2019 AEST, First published: 23:26 06 May 2019 AEST

empty boardroom
PRP is designed to target tumors in pancreatic, ovarian and colorectal cancers

Propanc Biopharma Inc (OTCMKTS:PPCB) welcomed the co-inventor of its flagship drug back to its scientific advisory board, the company announced Monday.

Ralf Brandt, who helped the metastatic cancer treatment company develop its drug PRP, returns to the board after resigning in 2018.

He spent seven years on the board before stepping down to oversee the merger of vivoPharm, an oncology discovery company he co-founded.

READ: Propanc CEO looks to harness power of pancreatic enzymes in cancer fight

“We are pleased to welcome Dr. Brandt back to our scientific advisory board,” CEO James Nathanielsz said. “He played a pivotal role in advising the company, which enabled us to complete our preclinical development activities for the advancement of PRP to a first-in-human study in cancer patients. We look forward to his continued support and guidance, as we now focus our attention towards preparing for the planned clinical trial and progressing PRP through early stage clinical development.”

PRP is a treatment designed to target tumors in pancreatic, ovarian and colorectal cancers. Metastatic cancer, which Propanc focuses on, occurs when cancer cells spread to other areas of the body.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Propanc Biopharma appoints Ralf Brandt to scientific advisory board as it...

Propanc Biopharma Inc (OTCMKTS:PPCB) chief executive officer James Nathanielsz speaks to Procative Investors about the company's recent appointment of Dr Ralf Brandt to its scientific advisory board.   The company is developing patents for cancer treatment that focuses on solid...

on 15/5/19